Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Auryxia (ferric citrate)
- erdafitinib
Interactions between your drugs
ferric citrate erdafitinib
Applies to: Auryxia (ferric citrate), erdafitinib
Using erdafitinib together with ferric citrate may alter the levels of phosphate in the blood, which may affect the dose of erdafitinib. Your doctor will check your blood phosphate level between 14 and 21 days after starting treatment with erdafitinib and then monthly, and may change your dose if necessary. Talk to your doctor if you have any questions or concerns. Contact your doctor as soon as possible if you develop signs and symptoms of high phosphate levels in the blood (hyperphosphatemia) such as muscle cramps, convulsions, tingling or numbness around the mouth, and bone pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ferric citrate food
Applies to: Auryxia (ferric citrate)
Food may reduce the absorption and blood levels of ferric citrate. In addition, some oral medications can also interfere with ferric citrate absorption into the bloodstream, which may make the medication less effective in treating your condition. Likewise, ferric citrate may interfere with the absorption of other orally administered medications. You should take ferric citrate on an empty stomach at least one hour before or two hours after a meal. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Talk to your doctor or pharmacist if you have questions about how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Carafate
Carafate is an anti-ulcer medication used to treat active duodenal ulcers. Learn about side ...
Renvela
Renvela (sevelamer) reduces blood levels of phosphorus in people with chronic kidney disease who ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Ibsrela
Ibsrela (tenapanor) is used for the treatment of irritable bowel syndrome with constipation ...
Velphoro
Velphoro (sucroferric oxyhydroxide) is used to treat hyperphosphatemia in chronic kidney disease ...
Xphozah
Xphozah (tenapanor) is a phosphate absorption inhibitor that is used lower serum phosphorus levels ...
Fosrenol
Fosrenol (lanthanum carbonate) reduces phosphate levels in patients with end stage renal disease ...
Renagel
Renagel (sevelamer) is used to reduce levels of phosphorus in people with kidney disease who are on ...
Lanthanum carbonate
Lanthanum carbonate is used for hyperphosphatemia of renal failure
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.